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With the imminent availability of ultra-high-volume genotyping platforms (on the order of 100,000–1,000,000
genotypes per sample) at a manageable cost, there is growing interest in the possibility of conducting genomewide
association studies for a variety of diseases but, so far, little consensus on methods to design and analyze them. In
April 2005, an international group of 1100 investigators convened at the University of Southern California over
the course of 2 days to compare notes on planned or ongoing studies and to debate alternative technologies, study
designs, and statistical methods. This report summarizes these discussions in the context of the relevant literature.
A broad consensus emerged that the time was now ripe for launching such studies, and several common themes
were identified—most notably the considerable efficiency gains of multistage sampling design, specifically those
made by testing only a portion of the subjects with a high-density genomewide technology, followed by testing
additional subjects and/or additional SNPs at regions identified by this initial scan.
Introduction
A traditional means of discovering disease genes begins
with family-based linkage scans, looking for regions of
the genome that tend to be transmitted through families
in a manner that parallels the transmission of the trait,
followed by a variety of fine-mapping techniques. This
approach has been highly successful for mapping major
genes responsible for Mendelian disorders, in part be-
cause the breadth of a linkage signal means that a ge-
nomewide scan can be accomplished with a few hundred
microsatellite or a few thousand SNP markers. However,
finer resolution of the putative risk susceptibility loci
through linkage analyses will only be feasible with the
availability of sufficient recombination events, requir-
ing large pedigrees (Boehnke 1994), and the utility of
the linkage approach for identifying multiple low-pen-
etrance variants involved in common diseases has been
questioned.
As an alternative, the past decade has seen a rapid
escalation in hypothesis-driven candidate gene associ-
ation studies or fine-mapping studies exploiting linkage
disequilibrium (LD), but these have usually been re-
stricted to a few dozen genes. Recent advances in high-
volume genotyping technology have now made it pos-
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sible to consider using empirical LD patterns to search
the genome for risk-associated variants. These studies
are based on the premise that “unrelated” individuals
are more distantly related than subjects from large ped-
igrees, thus allowing for sufficient recombination events
to have taken place (Nordborg and Tavere´ 2002). Cou-
pled with the efforts by the International Haplotype
Mapping (“HapMap”) Project (Gibbs et al. 2003) to
catalog millions of SNPs and haplotypes across diverse
populations and to use these to identify subsets of high-
ly informative “tag” SNPs, genomewide association
scans involving hundreds of thousands or more markers
on thousands of subjects—first suggested a decade ago
by Risch and Merikangas (1996)—are now a real
possibility.
Numerous research groups are planning or have un-
derway genomewide searches for a range of disorders
and the first reports of such studies (using early versions
of high-density SNP chips) are just beginning to appear
(Ozaki et al. 2002; Klein et al. 2005). These groups are
using a variety of population-based and family-based
epidemiological designs or model organisms, but so far
there has been little general discussion of how best to
design and analyze such studies. In April 2005, an in-
ternational group of 165 investigators met at the Uni-
versity of Southern California for a 2-day workshop to
discuss their efforts and consider various methodolog-
ical problems. This report provides a brief summary of
the major themes addressed at this workshop and a
review of the relevant background literature. The reader
is also referred to several recent review articles (Hirsch-
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horn and Daly 2005; Wang et al. 2005; Palmer and
Cardon, in press).
The workshop started with descriptions of some on-
going and planned genomewide association studies.
Eleven studies were described and the diseases under
study included breast, colorectal, and prostate cancer,
type I diabetes, age-related macular degeneration (AMD),
Parkinson disease, and systemic lupus erethematosis
(SLE). A study in northern Finland is collecting data on
a wide range of phenotypes (e.g., birth defects, neu-
rological outcomes, mental illness/personality traits,
asthma, cardiovascular events, infections, and diabetes),
enabling investigators to study a range of phenotypes
simultaneously in the same genomewide scan. Most of
the studies were not isolated efforts but were integrated
into research programs that usually included candidate-
gene association studies and sometimes included linkage
studies using affected-pair designs. All of the studies
either are using or plan to use some version of a mul-
tistage design, and none employ pooling of DNA. They
differ in the number of stages, ranging from two to four;
in criteria for case selection, with some electing to en-
hance the initial series with “genetically enriched” cases
and some not to; and in the nature of the control group,
with some using population-based and some using fam-
ily-based controls. The number of SNPs currently typed
at each stage also differed between studies; although all
groups expressed interest in eventually using the 500K
panel from Affymetrix (and some are using early-access
versions now), they wondered about the actual coverage
of that panel. The morning session closed with a de-
scription of the research opportunities that derive from
studying admixed populations, focusing on Hispanic/
Latino populations, and with a discussion of the ad-
vantages of studying nonhuman model organisms and
of how such studies would complement studies on hu-
man populations. More-detailed descriptions of each
presentation are provided in appendix A (online only).
The first afternoon began with a series of presenta-
tions about genotyping technologies and bioinformatics
support. Appendix A (online only) provides some details
about the currently available early-release 100–500K
SNP platforms from Illumina, Affymetrix, and other
companies, as well as the Genetrix bioinformatics suite.
Epidemiologic Study Design
Although the case-control design has become the work-
horse of genetic association studies, there has been con-
siderable discussion about its merits relative to cohort
studies, nested case-control or case-cohort designs, and
family-based designs (Langholz et al. 1999; Witte et al.
1999; Cardon and Bell 2001; Clayton and McKeigue
2001; Thomas and Witte 2002; Cardon and Palmer
2003). Lyle Palmer noted that one of the advantages of
the cohort design is that it allows for many disease end-
points to be considered simultaneously using a common
set of controls that he dubbed “universal controls” (Pal-
mer and Cardon, in press).
Sobell et al. (1993) first suggested a two-stage design
for association studies, which has recently been ex-
tended to genomewide scale by Satagopan and col-
leagues (2002, 2003, 2004), Lowe et al. (2004), and
van den Oord and Sullivan (2003). An initial sample of
subjects is tested for a dense set of markers, and then
an independent sample is tested only on a subset of
the most “significant” markers. They describe methods
for optimizing the numbers of subjects and significance
levels at each stage to maximize power, subject to a
constraint on cost and the overall type I error rate.
Jaya Satagopan demonstrated that the two-stage design
could yield substantial cost savings over a one-stage
design with the same test size and power. She also dis-
cussed likelihood inference for a quantitative trait locus
(QTL), optimizing by selective sampling of subjects with
extreme trait values. A related problem for testing single
candidate genes was recently considered by Thomas et
al. (2004), in which a relatively small sample was used
to select tag SNPs, which were then tested in the full
study. Both designs use all the data from both samples
in the final analysis. Duncan Thomas and Daniel Stram
described some extensions of the Satagopan et al. ap-
proach for the design of the CFR and MEC genomewide
studies. For these studies, it appears that the optimal
design typically entails allocating 80%–90% of the
costs to the first stage, with a significance level of
∼0.001–0.005 at the first stage. This can be expected
to yield ∼500–2,500 loci to be tested at the second stage
at a significance level of ∼0.00001. A sample size of
∼2,000 subjects at stage 1 and ∼2,000 at stage 2 would
be expected to yield 80% power for detecting a locus
with allele frequency 10% conferring a relative risk of
1.3, at an overall (“experimentwise”) type I error rate
of 5% and a total cost of ∼$5 million. Extensions re-
quired for these calculations involve different costs at
the two stages, allowance for the for prediction of2r
unobserved causal SNPs, and use of additional markers
at the second stage (see illustrative calculations in ap-
pendix A [online only]).
Other design considerations include whether to use
a family-based or population-based design and whether
to use stratified sampling to enrich one or more of the
stages for genetically predisposed cases. The appropriate
choice depends in part on whether one intends a search
for common polymorphisms having main effects on dis-
ease risk or those having modifying effects on other
genes or environmental factors, as well as prior beliefs
about the “common disease common variant” (Cargill
and Daley 2000; Reich and Lander 2001; Lohmueller
et al. 2003) versus “multiple rare variant” (Pritchard
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2001; Pritchard and Cox 2002; Wang et al. 2003; Fearn-
head et al. 2004) hypotheses. Although restriction of
the case series to those with a positive family history
can be effective at enriching for genetic susceptibility, it
risks introducing cryptic relatedness, since cases may
share greater kinship with one another than controls,
particularly in small regions or population isolates. Se-
lecting cases on the basis of “severity” could also have
the counterproductive effect of enriching environmental
as well as genetic factors. Genomewide scans could also
be used to identify genes that interact with particular
environmental agents or other modifying factors al-
ready known to play a major role in the etiology of a
particular disease. Stratifying on microsatellite insta-
bility (MSI) in colorectal tumors or restricting to MSI-
stable cases—or stratifying on family history, age, or
any of a number of other factors—might lead to greater
etiologic homogeneity and improve power for detecting
single-gene effects.
The problem of population stratification has been
widely debated (Wacholder et al. 2000; Thomas and
Witte 2002; Wacholder et al. 2002; Cardon and Palmer
2003; Freedman et al. 2004). David Clayton noted that
this can lead to three distinct problems: confounding;
cryptic relatedness, resulting in overdispersion of the
test statistic; and selection bias. Unlike some other bi-
ases, these problems do not become smaller with in-
creasing sample size—on the contrary, the potential in-
flation of type I error rates will be much larger in studies
of the size needed to demonstrate significance at the
genomewide scale. Family-based case-control designs
offer protection from population stratification, but at
the expense of some loss of power from “overmatching”
on genotype. The availability of an enormous number
of unlinked markers might provide ample opportunity
to control for population stratification by the methods
of genomic control (Devlin et al. 2001), structured as-
sociation (Pritchard et al. 2000), or simple logistic re-
gression (Tang et al. 2004) in studies using unrelated
controls. Although population stratification will gen-
erally cause overdispersion of test statistics (thereby in-
flating significance levels overall), the significance of any
specific test could be either increased or decreased. Thus,
the genomic control method, while yielding a test pro-
cedure with the correct type I error rate, may suffer
from some power loss. It is not known whether the
structured association method, which aims to correct
each association by stratifying on individual ancestry
estimates, would suffer from power loss to the same
extent, but it would require a much more computa-
tionally intensive analysis.
Population Selection
White populations have hitherto been the primary focus
of most association studies, and one of the populations
being intensively studied in the HapMap and other ge-
nomic variation projects. An open question remains
about the “transferability” to other populations of a
panel of tag SNPs that has been optimized for whites
(Carlson et al. 2003; Mueller et al. 2005). Duncan Tho-
mas described preliminary simulation studies suggesting
that a testing procedure that combines a test of overall
race-adjusted association and a test of race heterogeneity
(each tested at significance level a/2) could yield higher
power than either test alone (at level a), even under the
hypothesis that the relative risk for an unobserved caus-
al variant was the same across populations. The true
relative risk for a causal variant might also be expect-
ed to vary across populations because of interactions
with other genes or environmental factors with differing
prevalence.
Itsik Pe’er discussed the utility of isolated populations
for association studies because of their reduced genetic
diversity, longer LD, and extreme phenotype frequencies
for particular conditions. As an example, he described
efforts to construct a haplotype map for the Kosrae
population of Micronesia, an isolate for ∼2,000 years
with European admixture beginning in the 19th century
(Wijsman et al. 2003). These data are based on typing
100,000 SNPs with the 100K GeneChip in 30 parent-
child trios. Although the general patterns of allele fre-
quencies and decay of LD were similar to the non-Af-
rican HapMap data, there was a striking excess of
single-copy alleles, with 14 individuals carrying 80% of
these rare alleles and a tendency for them to cluster
along the genome, suggesting the effects of recent Eu-
ropean admixture. This implies a modest improvement
in power for single-marker associations and less diver-
sity in long-range haplotypes.
Marker Selection
Eric Jorgenson and John Witte elaborated on the relative
merits of “map-based” (i.e., uniformly spaced and or
tagSNPs) versus function or “gene-based” (i.e., occur-
ring only in coding, splice site, regulatory regions, and
or highly conserved intronic regions) approaches to
whole genome association studies (Collins et al. 1997;
Tabor et al. 2002; Botstein and Risch 2003; Carlson et
al. 2004; Neale and Sham 2004; Palmer and Cardon, in
press). They described sample size and cost calculations,
concluding that the gene-based approach would be con-
siderably less expensive, because of the reduction in the
number of SNPs that must be genotyped and the re-
sulting smaller sample sizes required, but would un-
doubtedly miss some potentially relevant regions (e.g.,
enhancers). A map-based approach would also be likely
to miss effects of some variation in genes, unless the
panel included adequate density of markers within genes
(see appendix A [online only] for discussion).
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Statistical Analyses
Two main approaches have been advocated for testing
gene associations: a “direct” method, based on a simple
x2 test for association, and an “indirect” method, based
on associations with haplotypes inferred from unphased
multilocus genotypes (Schaid et al. 2002; Zaykin et al.
2002; Stram et al. 2003), the haplotypes being assumed
to carry information about possibly unobserved causal
variants in the region. In a genomewide context, either
approach involves testing an enormous number of hy-
potheses simultaneously, thereby raising the problem of
multiple comparisons. Bonferroni correction is one com-
monly used approach to address this problem, requiring
an extremely small P value (say, )70.05/500,000p 10
to claim genomewide significance for any particular
SNP—or an even smaller P value if multiple subgroups,
additional markers, or multiple methods of analysis
(e.g., SNPs and haplotypes) are considered. Others have
suggested a Bayesian approach, such as the False Positive
Report Probability (Wacholder et al. 2004), requiring
explicit consideration of the prior probability for each
hypothesis under consideration. Under the assumption
that there could be many true positive associations, how-
ever, the Bonferroni correction is too conservative, and
a variety of methods based on the False Discovery Rate
have been advocated (Benjamini and Hochberg 1995;
Efron and Tibshirani 2002; Sabatti et al. 2003; Storey
and Tibshirani 2003).
Two papers have recently proposed analytic ap-
proaches for genomewide association studies that go
well beyond simple exhaustive testing of all SNPs sep-
arately. Lin et al. (2004) proposed exhaustive testing of
haplotype associations over all possible windows of seg-
ments, using a computationally efficient permutation
procedure to assess the significance of these correlated
tests. Marchini et al. (2005) proposed exhaustive testing
of all possible pairwise gene-gene interactions. Nelson
Freimer introduced the idea of haplotype sharing among
case-case pairs as an alternative to case-control asso-
ciation; Duncan Thomas provided a formal test of
haplotype sharing and showed how this test could be
decomposed into principal components representing
case-control associations with clusters of similar hap-
lotypes, in the spirit of Tzeng et al. (2003), Nyholt
(2004), and Lin and Altman (2004).
It is generally agreed that no amount of association
testing in epidemiological studies alone can distinguish
between the true-positive and false-positive signals ob-
tained in a multistage genomewide scan (Page et al.
2003). Approaches that could be taken at this stage
might include comparative genomics (Sidow 2002; Be-
jerano et al. 2004), linkage analysis of expression data
(Morley et al. 2004), or computational approaches to
predicting function (Ng and Henikoff 2003; Taylor and
Greene 2003; Livingston et al. 2004; Xi et al. 2004;
Zhu et al. 2004), before launching into the labor-inten-
sive and time-consuming process of developing func-
tional tests. Eleazar Eskin illustrated this by incorpo-
rating predictions of variation function, using as an
example the Chromogranin A gene (CHGA) involved
in hypertension. By use of the HAP phasing algorithm
(Hinds et al. 2005), six common haplotypes were iden-
tified, one of which appeared to be strongly associated
with the trait. A combination of comparative genomic
analysis and known binding-site analysis identified a
specific variant that could be responsible, G462A,
shown by in vitro assay to alter reporter expression.
Chiara Sabatti discussed the interpretation of stretches
of homozygosity, using data on Costa Rican case-parent
trios with Bipolar-1 disorder, typed at ∼3,000 SNPs on
chromosome 22. She described a hidden Markov model
approach to estimation of the inbreeding coefficient
from genomic data (Leutenegger et al. 2003), which
showed that all but three of parents had estimated in-
breeding coefficients of zero. Another possible expla-
nation for long homozygous stretches is large-scale copy
number variation (Iafrate et al. 2004; Sebat et al. 2004).
She discussed the applicability of methods used to deal
with genomic losses in cancer (Newton et al. 1998) to
other types of phenotypes, but she concluded that, with-
out a good model for instability, such techniques were
more useful for evaluating the likelihood of seeing par-
ticular stretches of large-scale copy number variation
than for detecting their existence.
Power
David Clayton showed the sample-size requirements for
a single-stage association study using both the direct and
indirect approaches (see appendix A [online only]). At
a marker density on the order of 1 every 6 kb (500,000
markers), we expect that most associations would be
detected indirectly by LD rather than with causal vari-
ants directly. Under the assumption that an average of
8 tag SNPs would yield an r2 of 0.8 and with the use of
an 8-df test, the sample sizes required for such indirect
associations would be slightly less than double those that
would be needed for a direct association.
Paul de Bakker summarized a comparison of various
SNP selection and analysis methods, using simulations
based on the HapMap-ENCODE regions, representa-
tive 500-kb regions of the genome with complete as-
certainment of common variation in 270 individuals
(ENCODE Project Consortium 2004). By nominating
all common SNPs as a causal allele, one by one, they
generated simulated case-control data sets, from which
they computed the power to detect an association under
different tagging and testing scenarios. They found that
choosing tag SNPs from a 5-kb panel (such as the Phase
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I HapMap) gave surprisingly good power for common
(15% frequency) causal alleles, and that specified hap-
lotype-based tests further improved genotyping effi-
ciency—a 33% reduction in the number of tag SNPs
required, with no loss of power. Additional sliding win-
dows of haplotypes did not help for common causal
alleles, once the increase in the number of tests was
allowed for, but there was some improvement in power
when the causal allele was rare (minor allele frequency
[MAF] ! 5%).
Daniel Stram described similar simulations, focusing
on the power of some very simple analyses of whole
genome scans using tag SNPs. Power is determined by
the noncentrality parameter, a function of the causal
allele frequency, its true relative risk, and the r2 for the
prediction of the unobserved causal variant by nearby
SNP(s). For relatively small regions, a Bonferroni-ad-
justed single-SNP analysis is generally more powerful
than a multivariate test of association, but, on a ge-
nomewide scale, the effective number of “independent”
tests is a function of the extent of LD. By determining
the block structure, choosing tag SNPs within blocks,
conducting multivariate tests within each block, and
applying a Bonferroni correction for the number of
blocks instead, he showed that this method yielded bet-
ter power than simply using all SNPs with Bonferroni
correction for the number of SNPs.
Genotyping Errors
David Clayton noted that genotyping errors are gener-
ally assumed to be nondifferential (i.e., not related to
phenotype), leading to some loss of power and bias in
relative risk estimates towards the null, but no increase
in type I errors (except in case-parent trio designs). How-
ever, he pointed out that it may be difficult to ensure
that all aspects of DNA processing and analysis are the
same for cases and controls, particularly if the ascer-
tainment of these two groups is not concurrent. To test
this assumption, he showed data from a study of non-
synonymous SNPs (nsSNPs) and type I diabetes, which
revealed that some of the overdispersion of association
tests that were not obviously true positives could be
explained by questionable allele calls or by those not
replicated on another platform, as well as by regional
stratification and substructure (see appendix A [online
only] for additional details of this analysis). Particularly
disturbing were shifts between cases and controls in the
point clouds corresponding to each genotype, presum-
ably due to differences in DNA processing. Standard
laboratory practice of using blinded samples to deter-
mine the parameters for allele calling could thus lead to
differential misclassification (with consequent inflation
of type I error rates and relative risk estimates biased
away from the null). Instead, it would appear that, to
minimize such misclassification, it would be necessary
to calibrate the software separately for each group.
Derek Gordon showed the effects of nondifferential
genotyping error on both family-based and population-
based tests of association. For case-parent trio data,
even nondifferential errors can inflate type I error rates
(Mitchell et al. 2003). To overcome this problem, Gor-
don et al. (2001) introduced the likelihood-based
TDTae (“adjusted for errors”). Similar issues have been
addressed for case-control designs using unrelated in-
dividuals (Rice and Holmans 2003). Phenotyping errors
would be expected to have similar effects. Recent work
on the use of double sampling, combining fallible meth-
ods on a large sample with a “gold standard” method
on a subset, appears to improve power for tests of as-
sociation (Gordon et al. 2004). Methods that formally
incorporate information on accuracy of genotype or
haplotype calls into the statistical test of association
(Hao and Wang 2004) have some potential for exten-
sion to the whole-genome scale.
DNA pooling has been suggested as an efficient pro-
cedure for screening many samples for differences in
allele frequencies at many loci (Bansal et al. 2002; Sham
et al. 2002). Various authors have discussed experi-
mental design for such studies (Barratt et al. 2002; Pfeif-
fer et al. 2002; Sham et al. 2002), including the number
of pools and pool sizes needed for accurate allele fre-
quency determination. The general sense of the partic-
ipants was that this approach is not sufficiently reliable
for use on a genomewide scale at this time, despite its
obvious cost appeal.
Conclusions
All genomewide association studies of human popula-
tions that have been described above are using or plan
to use a multistage design, and none are proposing to
use DNA pooling. Studies differ in the number of stages
and in the nature of cases and controls selected for each
stage. Some of the studies in the United Kingdom and
the CFRs employ a strategy that aims to enhance ge-
netically caused cases, while others (e.g., the AMD
study) choose not to employ such a strategy. There was
general agreement that it is probably helpful to decrease
heterogeneity in the case series, either by exclusion of
selected subgroups (e.g., exclusion of colorectal cancer
cases on the basis of MSI-H tumors or evidence of a
germline mutation in a mismatch repair gene) or by a
stratified selection that would ensure sufficient sample
size in the major strata of interest. In the study of cancer,
there is growing recognition of the value of using mo-
lecular markers derived from the tumor to define sources
of heterogeneity. Similar markers are under development
with other diseases. Thus, even for diseases like cancer
that are traditionally analyzed as simple dichotomous
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phenotypes, there are often several dimensions on which
to characterize cases; for other diseases, like diabetes,
the number of variables needed to fully characterize the
phenotype can be very large. A genomewide scan for
genomic determinants of gene expression levels, for ex-
ample, would entail potentially many billion compari-
sons; several such scans are currently underway.
Advantages and disadvantages of alternative control
series, usually discussed in the context of candidate gene
studies (e.g., trade-offs between power and control of
population stratification), are also relevant to genome-
wide association studies. Some studies—for example,
the CFRs—are in a position to use both types of controls
and currently plan to use unrelated controls in stage 1
to enhance power and family-based controls in stage 2.
If the main objective of a second stage is to replicate
the findings of a first stage, then one needs to be mind-
ful about introducing possible sources of heterogeneity
(e.g., by using different types of cases or controls) be-
tween stages, which will complicate interpretations of
results.
Most studies are not or do not plan to incorporate
information on environmental exposures in the early
stages of the genomewide studies. This concerned some
investigators, since genomewide scans could miss im-
portant genetic causes where the effect of the gene is
only detectable when information on the relevant en-
vironmental exposure(s) is incorporated into the anal-
yses, particularly since common genetic variants for
common diseases may plausibly interact with environ-
mental exposures.
Several very general issues were raised in the con-
cluding discussion. Alice Whittemore began by asking
(1) Is the technology driving the science? (2) Can we
afford the technology? (3) When is an association scan
unwarranted? and (4) When it is warranted, how can
the epidemiology and biology of the disease drive our
choice of design? An example where such an approach
might not be warranted is Hodgkin disease, in which
the risk to DZ twins is very low and the risk to MZ
twins nearly 100% (Mack et al. 1995), suggesting mul-
tiple rare variants (Risch 1990), a scenario not amenable
to association mapping. Robert Haile asked whether the
time was ripe in terms of the technology development,
the need for coordination by the many investigators
who are likely to be proposing such studies in the near
future for a range of diseases and even for different
species, and how best to deal with the problems of eti-
ologic heterogeneity and complexity. Nevertheless, there
seemed to be a broad consensus that the time was in-
deed ripe for launching the first generation of genome-
wide association studies, but that each would require
careful justification and coordination among groups
studying similar conditions to ensure optimal allocation
of the limited resources available for such expensive
undertakings.
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